Patent Application
20230363418
The present invention relates to a composition for preventing, treating or ameliorating neuropsychologic diseases, comprising a mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF), a peptide derived therefrom, or a fragment thereof.
Neuropsychologic disease refers to a condition in which an imbalance of brain neurotransmitters and genetic, social and environmental factors work in combination to cause abnormalities in thinking, emotion and behavior, and the major examples thereof include depression, anxiety disorder, schizophrenia, dependence, epilepsy, autism spectrum disorder (ASD; autism), attention deficit hyperactivity disorder (ADHD), developmental disorder, and mental retardation disorder. Among them, the autism is known to be caused by genetic mutations in germ cells due to paternal stress, drinking, advanced pregnancy, etc. The current incidence rate has been reported to be 1.5%, but the incidence rate is increasing worldwide, and especially in Korea, there is a report that it has increased to 2.6%. In addition, neuropsychologic diseases such as ADHD and mental retardation disorder are also on the rise, and these diseases are diagnosed early within 3 years from childbirth, so treatment is required at an early stage of onset.
In particular, neuropsychologic diseases including autism, ADHD, schizophrenia, and epilepsy are caused by complex problems of many genes, but in most brain diseases, specific nerve cell death and synapse formation problems, resulting in imbalance of neurotransmitters, lack of inhibitory GABA (γ-aminobutyric acid), regulation of synapse generation, and pruning are attracting attention as the causes. However, although their fundamental treatment is to promote nerve regeneration, proliferation of nerve stem cells, and differentiation of GABAergic nerve cells, few therapeutic agents for such fundamental treatment have been researched and developed yet.
The present inventors have confirmed that a mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF), which is one of 16 or more growth factors secreted into nerve stem cells by cerebrovascular cells, has an ameliorating effect on brain diseases such as autism, ADHD, mental retardation and developmental disorders accompanied by memory impairment, thereby completing the present invention.
One object of the present invention is to provide a pharmaceutical composition for preventing or treating neuropsychologic diseases, the composition comprising, as an active ingredient, (a) a mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF); or (b) a peptide derived therefrom, or a fragment thereof.
Another object of the present invention is to provide a method for preventing or treating neuropsychologic diseases, comprising administering the composition to an individual.
Still another object of the present invention is to provide a health functional food composition for preventing or ameliorating neuropsychologic diseases, the composition comprising, as an active ingredient, (a) MANF; or (b) a peptide derived therefrom, or a fragment thereof.
Yet another object of the present invention is to provide a feed composition for preventing or ameliorating neuropsychologic diseases, the composition comprising, as an active ingredient, (a) MANF; or (b) a peptide derived therefrom, or a fragment thereof.
The administration of a mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF), a peptide derived therefrom or a fragment thereof according to the present invention promotes the differentiation of cholinergic and/or GABAergic (γ-aminobutyric acid) nerve cells in memory impairment and autism models to induce nerve regeneration, exhibits effects of enhancing memory and ameliorating anxiety disorders, and ameliorates social cognition, sociability and decline in social sexual preference, whereby a composition for preventing or treating neuropsychologic diseases such as autism, ADHD, mental retardation disorder, and developmental disorder can be provided.
Hereinafter, the present invention will be described in more detail. Meanwhile, descriptions and embodiments disclosed in the present invention may also be applied to other descriptions and embodiments, respectively. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be said that the scope of the present invention is limited by the specific descriptions described below. In addition, many equivalents to the specific embodiments of the invention described herein can be recognized or ascertained by those skilled in the art using no more than routine experimentation. Also, such equivalents are intended to be encompassed by the present invention.
One aspect of the present invention for achieving the above object is to provide a pharmaceutical composition for preventing or treating neuropsychologic diseases, the composition comprising, as an active ingredient, (a) a mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF), or (b) a peptide derived therefrom, or a fragment thereof.
As used herein, the term “neuropsychologic disease” refers to a condition in which an imbalance of brain neurotransmitters and genetic, social and environmental factors work in combination to cause abnormalities in thinking, emotion and behavior, and the major examples thereof include depression, anxiety disorder, schizophrenia, dependence, epilepsy, autism spectrum disorder (ASD; autism), attention deficit hyperactivity disorder (ADHD), developmental disorder, and mental retardation disorder, which belong to neuropsychologic disease.
In the present invention, the neuropsychologic disease may be any one or more selected from the group consisting of autism, ADHD, mental retardation disorder and developmental disorder, but is not limited thereto.
In addition, in the present invention, the neuropsychologic disease may be accompanied by memory impairment, but is not limited thereto.
As used herein, the term “mesencephalic growth factor (mesencephalic, astrocyte-derived neurotrophic factor; MANF)” is one of 16 or more growth factors secreted into nerve stem cells by cerebrovascular cells, and may be used interchangeably with mesencephalic growth factor.
The MANF may have an amino acid sequence of SEQ ID NO: 1, consist of an amino acid sequence of SEQ ID NO: 1, or include an amino acid sequence set forth in SEQ ID NO: 1, but is not limited thereto. The sequence of SEQ ID NO: 1 can be confirmed in NCBI Genbank, a known database.
Specifically, the MANF may have SEQ ID NO: 1 and/or an amino acid sequence having at least 70% homology or identity with SEQ ID NO: 1. In addition, as long as it is an amino acid sequence having such homology or identity and exhibiting a function corresponding to the MANF, it is apparent that a MANF having an amino acid sequence in which a part of the sequence is deleted, modified, substituted or added is also included within the scope of the present invention.
That is, although it is described as ‘a protein or polypeptide including an amino acid sequence described in a specific sequence number’ or ‘a protein or polypeptide consisting of an amino acid sequence described in a specific sequence number’ in the present application, it is obvious that a protein consisting of an amino acid sequence in which a part of the sequence is deleted, modified, substituted or added may also be used in the present invention, provided that it has an activity identical to or corresponding to that of a polypeptide consisting of the amino acid sequence of that SEQ ID NO. For example, it is apparent that a ‘polypeptide comprising an amino acid sequence of SEQ ID NO: 1’ may belong to a ‘polypeptide comprising an amino acid sequence of SEQ ID NO: 1’ if it has the same or corresponding activity.
As used herein, the term “MANF-derived peptide” may include any peptide selected from peptides constituting MANF without limitation, and specifically, the MANF-derived peptide may include two or more consecutive amino acids, and may also include a fragment thereof.
In the present invention, (a) MANF or (b) a MANF-derived peptide or fragment thereof may be included in the composition in any one form selected from the group consisting of a polypeptide sequence of MANF or a fragment thereof; a polynucleotide sequence encoding the polypeptide sequence or a fragment thereof; and a vector comprising the polynucleotide sequence, but is not limited thereto.
In the present invention, a gene encoding the MANF may include a base sequence encoding an amino acid sequence of SEQ ID NO: 1, and more specifically, may include, have, or consist of an base sequence of SEQ ID NO: 2, but is not limited thereto. The base sequence of SEQ ID NO: 2 may be obtained from GenBank, a known database.
As used herein, the term “polynucleotide” refers to a DNA or RNA strand having a certain length or longer, which is a polymer of nucleotides in which nucleotide monomers are covalently linked in a long chain shape, and more specifically, a polynucleotide fragment encoding the variant. The polynucleotide may be described as a gene if it is an aggregate of polynucleotides capable of functioning. In the present invention, the polynucleotide and the gene may be used interchangeably.
Specifically, the polynucleotide of the present invention may be subjected to various modifications in the coding region within a range that does not change the amino acid sequence of the polypeptide due to codon degeneracy or in view of codons preferred in an organism intended to express the polypeptide. Specifically, any polynucleotide sequence encoding MANF consisting of the amino acid sequence of SEQ ID NO: 1 may be included without limitation.
In addition, if it is a probe that can be prepared from a known gene sequence, for example, a sequence encoding the MANF consisting of the amino acid sequence of SEQ ID NO: 1 by hybridization with a sequence complementary to all or part of the base sequence under a stringent condition, it may be included without limitation. The term “stringent condition” means a condition that enables specific hybridization between the polynucleotides. Such a condition is well known in the art. For example, there can be exemplified a condition in which genes with high homology or identity, specifically genes having homology or identity of 40% or more, specifically 90% or more, more specifically 95% or more, even more specifically 97% or more, particularly specifically 99% or more hybridize to each other, and genes with lower homology or identity do not hybridize; or a condition of washing once, specifically 2 to 3 times at salt concentration and temperature equivalent to 60° C., 1YSSC, 0.1% SDS, specifically 60° C., 0.1YSSC, 0.1% SDS, more specifically 68° C., 0.1YSSC, 0.1% SDS, which are washing conditions for normal southern hybridization.
Hybridization requires that two nucleic acids have complementary sequences, although mismatches between bases are possible depending on the stringency of hybridization. The term “complementary” is used to describe the relationship between nucleotide bases capable of hybridizing to each other. For example, for DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Accordingly, the present invention may also include isolated nucleic acid fragments complementary to the overall sequence as well as substantially similar nucleic acid sequences.
Specifically, polynucleotides having homology or identity can be detected using hybridization conditions including a hybridization step at a Tm value of 55° C. and using the above-described conditions. In addition, the Tm value may be 60° C., 63° C., or 65° C., but is not limited thereto, and may be appropriately adjusted depending on the purpose by those skilled in the art.
The appropriate stringency for hybridizing polynucleotides depends on the length of the polynucleotides and the degree of complementarity, and the parameters are well known in the art (see Sambrook et al., supra, 9.50-9.51, 11.7-11.8).
As used herein, the terms “homology” and “identity” refer to a degree to which two given amino acid sequences or base sequences are related, and may be expressed as a percentage. The terms “homology” and “identity” can often be used interchangeably.
Sequence homology or identity of a conserved polynucleotide or polypeptide is determined by a standard arrangement algorithm, and a default gap penalty established by the program used may be used together. Substantially, homologous or identical sequences may generally hybridize to at least about 50%, 60%, 70%, 80%, or 90% or more of the total or full-length of the sequence under moderate or high stringent conditions. Hybridization also considers polynucleotides containing degenerate codons instead of codons in polynucleotides.
The homology or identity of the polypeptide or polynucleotide sequence can be determined, for example, by an algorithm BLAST according to the literature [see: Karlin and Altschul, Pro. Natl. Acad. Sci. USA, 90, 5873(1993)], or FASTA by Pearson (see: Methods Enzymol., 183, 63, 1990). Based on such an algorithm BLAST, a program called BLASTN or BLASTX has been developed (see http://www.ncbi.nlm.nih.gov). In addition, whether or not any amino acid or polynucleotide sequence has homology, similarity or identity can be confirmed by comparing the sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions are within the scope of the art, and can be determined by methods well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989; F.M. Ausubel et al., Current Protocols in Molecular Biology).
As used herein, the term “vector” refers to a DNA product containing a polynucleotide sequence encoding a desired protein in a suitable host in a form operably linked to a regulatory sequence suitable for expressing the target protein. The expression regulatory sequence may include a promoter capable of initiating transcription, an operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence regulating the termination of transcription and translation. After transformation into an appropriate host cell, the vector can replicate or function independently of the host genome, and can be integrated into the genome itself.
The vector used in the present invention is not particularly limited as long as it can be used for gene therapy while replicating in a host cell, and any vector known in the art may be used. For example, examples of vectors commonly used for gene therapy include viral vectors or non-viral vectors in a natural or recombinant state. As specific examples, the viral vector may include an adenovirus, a retrovirus, a lentivirus, an adeno-associated virus (AAV), an oncolytic virus, and a herpes simplex virus vector and the like, and non-viral vectors may include a plasmid and a liposome. Specifically, the vector usable in the present invention may be an AAV vector as a viral vector for gene therapy, but is not particularly limited thereto, and any known viral vector for gene therapy may be used.
Since the viral vector for gene therapy is infected only once during viral infection and does not proliferate the virus, it does not infect surrounding cells and is safely used for human treatment. Among them, AAV is recognized as the most stable type of vector when used clinically for human treatment, and is currently the most used vector in clinical gene therapy worldwide. The present invention may also include a viral vector in the form of a peptide, and may further include a viral vector in the form of a MANF-derived peptide containing a portion of the MANF sequence or various DNA vectors including the viral vector without limitation.
As used herein, the term “transformation” means that a recombinant vector containing a polynucleotide encoding a target protein is introduced into a host cell, and the protein encoded by the polynucleotide is expressed in the host cell.
In addition, the term “operably linked” as used herein means that the polynucleotide sequence is functionally linked to a promoter sequence or an expression regulatory region that initiates and mediates transcription of a polynucleotide encoding a target protein of the present invention. The operable linkage can be produced using a genetic recombination technique known in the art, and site-specific DNA cleavage and linkage can be made using cleaving and linking enzymes known in the art, but is not limited thereto.
In the present invention, the “target protein” may be MANF or a peptide derived therefrom or a fragment thereof. The MANF, MANF-derived peptide or fragment thereof according to the present invention may be included in the pharmaceutical composition in the form of: a polypeptide sequence of MANF or a fragment thereof; a polynucleotide sequence encoding the polypeptide sequence or a fragment thereof; or a vector comprising the polynucleotide sequence, thereby increasing the level of MANF in an individual to which the composition is administered and thus exhibiting an effect of preventing or treating neuropsychologic diseases.
As used herein, the term “prevention” refers to any action that suppresses or delays the onset of the neuropsychologic diseases by administration of the composition.
As used herein, the term “treatment” refers to any action that ameliorates or beneficially changes the symptoms of the neuropsychologic diseases by administration of the composition.
The pharmaceutical composition comprising the MANF, MANF-derived peptide or fragment thereof as an active ingredient according to the present invention may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition. In this case, the content of the active ingredient included in the composition is not particularly limited, but may include 0.0001 wt% to 10 wt%, preferably 0.001 wt% to 1 wt%, based on the total weight of the composition.
The pharmaceutical composition may have any one dosage form selected from the group consisting of: tablets, pills, powders, granules, capsules, suspensions, liquid for internal use, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories, and may be several oral or parenteral dosage forms. When formulated, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, internal solutions, emulsions, syrups, etc., which may contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives in addition to commonly used simple diluents such as water and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. As non-aqueous solvents and suspending agents, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, and the like may be used.
The composition of the present invention may be administered in a pharmaceutically effective amount.
As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level can be determined according to factors, including individual type and severity, age, sex, disease type, drug activity, drug sensitivity, administration time, administration route and discharge rate, treatment period, drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered individually or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. It may also be administered singly or multiply. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, and such amount can be easily determined by those skilled in the art. The preferred dosage of the composition of the present invention varies depending on the patient’s condition and weight, degree of disease, drug form, administration route and period, but for the desired effect, it is desirable that the pharmaceutical composition of this invention is administered at 0.0001 to 100 mg/kg, preferably 0.001 to 10 mg/kg per day. Administration may be made once a day, or divided several times. The composition may be administered to various mammals such as rats, livestock and humans through various routes, and may be administered without limitation by any conventional methods known in the art, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection.
In addition, the pharmaceutical composition of the present invention may also be used in the form of veterinary medicines as well as medicines applied to humans.
The MANF, MANF-derived peptide or fragment thereof according to the present invention can promote the regeneration of nerve cells in the hippocampus.
The MANF, MANF-derived peptide or fragment thereof according to the present invention can promote the differentiation of nerve cells.
Specifically, the MANF, MANF-derived peptide or fragment thereof according to the present invention can promote the regeneration of nerve cells by promoting the differentiation of cholinergic nerve cells and/or GABAergic (γ-aminobutyric acid) nerve cells.
In the present invention, a model of memory impairment and autism induced by ibotenic acid (IBO) was prepared.
The IBO is a compound that damages neurons of striatum, hippocampus formation, substantia nigra, and piriform cortex when injected into the brain of a rat. In specific experiments, by administering it to be injected into three areas in the entorhinal cordex, nerve damage to the dorsal and ventral sides of the hippocampus can be induced, leading to the memory damage and autism (Miyuki Sadamatsu, Congenital Anomalies 2006; 46, 1-9, Review of animal models for autism: implication of thyroid hormone).
Accordingly, in the memory impairment and autism model of the present invention, as the IBO was administered, the differentiation of cholinergic nerve cells in the ventral hippocampus region, which is an area of anxiety and social behavior, was reduced. However, in one embodiment of the present invention, when the MANF was administered, the differentiation of cholinergic nerve cells was increased (
Meanwhile, diseases such as attention deficit hyperactivity disorder, stroke, schizophrenia, and autism are known to be caused by an imbalance between excitatory cells and GABAergic nerve cells. In order to ameliorate these diseases, it is necessary to promote the production or differentiation of GABA, an inhibitory signaling substance, rather than an excitatory signaling substance with a complex signal transduction system. Among the genes involved in the differentiation into GABAergic nerve cells, the GAD (glutamic acid decarboxylase) gene is an enzyme that catalyzes the decarboxylation of glutamate, and is known to synthesize the GABA, an inhibitory neurotransmitter, through this process.
Accordingly, in another embodiment of the present invention, it was confirmed whether the MANF promotes differentiation into GABAergic nerve cells in the course of neural cell differentiation of primary neural progenitor cells. As a result, there was no significant change in the number of NeuN when treated with the MANF at a concentration of 30 ng/ml during the primary neural progenitor cell differentiation process, but GFP-positive cells increased compared to the Con group, which showed that the MANF promotes the differentiation into GABAergic nerve cells in the process of neural cell differentiation (
The MANF, MANF-derived peptide or fragment thereof according to the present invention can improve memory.
In one embodiment of the present invention, memory ability was measured for the memory impairment and autism model administered with IBO through a Y-shaped maze measurement method, a passive avoidance test, and a Morris water maze test, and all results indicated that the memory was enhanced (
The MANF, MANF-derived peptide or fragment thereof according to the present invention can ameliorate anxiety disorders.
In one embodiment of the present invention, anxiety behavior was measured for the memory impairment and autism model administered with IBO through a high cross-shaped maze experiment and an open space behavior test, and as a result, the anxiety behavior was reduced in the MANF-administered group compared to the IBO group or the positive control group (
The MANF, MANF-derived peptide or fragment thereof according to the present invention can improve sociability or social cognitive ability.
In one embodiment of the present invention, it was investigated whether or not social behavior, social cognition, sociability, and social sexual preference were restored by MANF administration through a behavioral experiment for the memory impairment and autism model administered with IBO, and the results indicated that social behavior, social cognition, sociability and social sexual preference were restored in the MANF-administered group compared to the IBO group or the positive control group (
In another embodiment of the present invention, brain tissues of the memory impairment and autism model after the behavioral experiment were analyzed, and as a result, cell death was significantly increased in the IBO-administered group, but the cell death was significantly suppressed in the MANF-AAV-hMSC-administered group compared to the IBO-administered group and the GFP-AAV-hMSC-administered group, from which it can be seen that the MANF inhibits death of brain nerve cells and increases survival in the memory impairment and autism model (
In still another embodiment of the present invention, brain tissues of the memory impairment and autism model after the behavioral experiment were analyzed, and as a result, in the MANF-administered group, the proliferation (BrdU+, Ki67) and migration (DCX) of neural stem cells (Sox2+) were promoted to enhance nerve regeneration (
As such, the present invention is meaningful in revealing for the first time that the MANF promotes the differentiation of cholinergic and/or GABAergic nerve cells in memory impairment and autism models to induce nerve regeneration, exhibits effects of enhancing memory and ameliorating anxiety disorders, and ameliorates social cognition, sociability and decline in social sexual preference, thereby exerting the effect of preventing or treating neuropsychologic diseases, especially autism, ADHD, mental retardation disorder, and developmental disorder.
In addition, a peptide derived from the MANF or a fragment thereof can also exhibit the same effect as the MANF as described above.
Another aspect of the present invention is to provide a method for preventing or treating neuropsychologic diseases, comprising administering the pharmaceutical composition of the present invention to an individual.
The terms used herein are as described above.
As used herein, the term “individual” refers to any animal, excluding humans, in which neuropsychologic diseases have occurred or may occur. By administering the pharmaceutical composition of the present invention to an individual suspected of having the neuropsychologic disease, the individual can be effectively treated.
As used herein, the term “administration” means the pharmaceutical composition of the present invention is introduced into an individual suspected of having a neuropsychologic disease by any suitable method, wherein the administration can be performed through various routes such as oral or parenteral, as long as it can reach the target tissue.
The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, as described above.
The pharmaceutical composition of the present invention may be applied to any individual for the purpose of preventing or treating neuropsychologic diseases without particular limitation. For example, it may be applied to non-human animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cattle, sheep, pigs, goats, etc., birds and fish, and the pharmaceutical composition may be administered parenterally, subcutaneously, intraperitoneally, intrapulmonaryly, or intranasally, and if necessary, may be administered by any suitable method including intralesional administration for local treatment. The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and weight of the individual, the degree of disease, the drug form, the route and period of administration, and can be appropriately selected by those skilled in the art. For example, the composition may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection, but is not limited thereto.
Still another aspect of the present invention is to provide a health functional food composition for preventing or ameliorating neuropsychologic diseases, the composition comprising, as an active ingredient, (a) MANF; or (b) a peptide derived therefrom, or a fragment thereof.
The terms used herein are as described above.
As used herein, the term “amelioration” refers to any action that ameliorates or benefits the symptoms of an individual suspected or diagnosed with a neuropsychologic disease by using the composition.
The food composition of the present invention may include a food-acceptable salt, and as such a salt, an acid addition salt formed by a food-acceptable free acid or a metal salt formed by a base is useful. For example, an inorganic acid and an organic acid may be used as the free acid. Hydrochloric acid, sulfuric acid, hydrobromic acid, sulfurous acid, phosphoric acid, or the like may be used as the inorganic acid, and citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, methanesulfonic acid, or the like may be used as the organic acid. In addition, an alkali metal salt or an alkaline earth metal salt, sodium salt, potassium salt or calcium salt may be used as the metal salt. However, it is not limited thereto.
The food composition of the present invention includes the form of pills, powders, granules, needles, tablets, capsules, liquids, or the like, and the food to which the composition may be added includes various foods, such as beverages, chewing gum, tea, vitamin complexes, and health supplements.
In addition to the active ingredient contained as an essential ingredient, the food composition of the present invention may include other ingredients without particular limitation, and may contain various herbal extracts, food supplement additives, natural carbohydrates, or the like as additional ingredients like conventional foods. The content of the active ingredient in the food composition may be suitably determined according to the purpose of use (prevention, amelioration or therapeutic treatment). In this case, the content of the active ingredient included in the composition is not particularly limited, but may include 0.0001 wt% to 10 wt%, preferably 0.001 wt% to 1 wt%, based on the total weight of the composition.
In addition, the food supplement additive may include food supplement additives commonly used in the art, for example, a flavoring agent, a sweetener, a coloring agent, a filler, a stabilizer, and the like.
Examples of the natural carbohydrate include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides, for example, conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent other than those described above, natural flavoring agents (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be advantageously used.
In addition to the above, the food composition of the present invention may include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages, and the like. In addition, it may contain the pulp for the production of natural fruit juice and fruit juice beverages and vegetable beverages. These components may be used alone or in combination.
In the present invention, the health supplement may include a health functional food and a health food.
The health functional food is the same term as food for special health use (FoSHU), and refers to a food with high medicinal and medical effects processed so that the bioregulatory function is efficiently exhibited in addition to nutritional supply. Here, the “function(al)” means having a useful effect for health use, such as nutrient regulation or physiological action for the structure and function of the human body.
Food comprising the food composition of the present invention can be prepared by a method commonly used in the art, and when prepared, raw materials and components commonly used in the art may be added. In addition, the food may also be prepared in any formulation without limitation as long as it is a formulation recognized as a food. The food composition of the present invention may be prepared in various forms of formulations; and unlike general drugs, since it uses food as a raw material, it has the advantage of not having side effects that may occur when taking drugs for a long time, and can be excellent in portability.
Yet another aspect of the present invention is to provide a feed composition for preventing or ameliorating neuropsychologic diseases, the composition comprising, as an active ingredient, (a) MANF; or (b) a peptide derived therefrom, or a fragment thereof.
The terms used herein are as described above.
As used herein, the term “feed” refers to any natural or artificial diet, one-meal, etc., or a component of the one-meal, which are intended to be eaten, ingested and digested by an animal, or suitable therefor.
The type of the feed is not particularly limited, and any feed commonly used in the art may be used. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton, or food. These may be used alone or in mixture of two or more, but is not limited thereto.
The feed composition of the present invention may be applied to the diet of many animals including mammals, poultry, fish and shellfish, that is, feed. Specifically, it may be used for commercially important mammals such as pigs, cattle, and goats, zoo animals such as elephants and camels, and livestock such as dogs and cats. Poultry of commercial importance may include chickens, ducks and geese, and may include commercially raised fish and crustaceans such as trout and shrimp.
In addition to the MANF, MANF-derived peptide or fragments thereof, the feed composition of the present invention may be further mixed for administration with one or more of: organic acids such as citric acid, fumaric acid, adipic acid, and lactic acid; phosphates such as potassium phosphate, sodium phosphate, and polymerized phosphate; natural antioxidants such as polyphenols, catechins, tocopherols, vitamin C, green tea extract, chitosan, and tannic acid. In addition, diluents, dispersants, surfactants, binders, or lubricants may be additionally added to prepare formulations for injections such as aqueous solutions, suspensions, emulsions, etc., capsules, granules, or tablets.
In addition, the feed composition of the present invention may be used together with various supplements such as amino acids, inorganic salts, vitamins, antioxidants, antifungal agents, and antibacterial agents as auxiliary ingredients, vegetable protein feed such as ground or crushed wheat, barley, and corn, animal protein feed such as blood meal, meat meal, and fish meal, nutritional supplements, growth promoters, digestion and absorption promoters, and disease preventives in addition to the main ingredients such as animal and vegetable fats.
The feed composition may include a feed additive. The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act.
When the feed composition of the present invention is used as a feed additive, the feed composition may be added as it is or be used together with other ingredients, and may be appropriately used according to a conventional method. The dosage form of the feed composition may be prepared as an immediate-release or sustained-release formulation in combination with a non-toxic pharmaceutically acceptable carrier. Such edible carriers may be corn starch, lactose, sucrose, propylene glycol. In the case of a solid carrier, it may be in dosage forms such as tablets, powders, and troches; and in the case of a liquid carrier, it may be in dosage forms such as syrups, liquid suspensions, emulsions, and solutions. In addition, the administration agent may contain preservatives, lubricants, solution accelerators, stabilizers, and may contain substances useful for the prevention, treatment or amelioration of other diseases.
Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
To determine the optimal dose of MANF to promote the expression of differentiation markers in neural progenitor cells, immunoblotting experiments were performed using NeuN antibody that labels the nuclei of mature neurons, glutamic acid decarboxylase (GAD65/67) and vesicular GABA transferase (vGAT) that label GABAergic nerve cells.
Specifically, hippocampal-derived neural stem cells were isolated from the brain of E16 rat embryos. Hippocampal ridges were minced from the embryonic forebrains of E16 rats using sterile fine tweezers under a dissecting microscope. The tissues were collected, mechanically separated using a pipette in Ca2+/Mg2+-freeHBSS (Invitrogen) solution, and planted at 19,000 cells/cm2 in 35 mm culture dishes precoated with 15 µg/ml poly-L-ornithine and 1 µg/ml fibronectin (Sigma). The cells were cultured under the condition of 5% CO2 for 3 days using a serum-free N2 medium (medium for proliferation) supplemented with 10 ng/mL basic fibroblast growth factor(bFGF, Invitrogen). Thereafter, the cells were removed using 0.05% trypsin/EDTA (ethylene-diamine-tetraacetic acid), and neural progenitor cells were planted on a 12 mm glass coverglass (Belco) for immunostaining and on a 100 mm dish for immunoblotting and cultured in N2 medium for proliferation containing bFGF for 1 day. Thereafter, in the proliferation condition, the medium continuously containing bFGF was treated with MANF at the indicated concentration and cultured for 2-3 days; and in the differentiation condition, MANF was added to the medium for differentiation not containing bFGF, which was cultured for 3-7 days. In the control group (vehicle), physiological saline was added in the same volume instead of MANF.
After 3-7 days of differentiation of the cultured neural stem cells, the medium was removed and washed once with PBS (Phosphate-buffered saline). Then, all the cells were lysed using a lysis buffer to which a protease inhibitor was added. The lysate was loaded in a 10% gel in the same volume, then transferred to a PVDF (Polyvinylidene Fluoride) membrane and blocked with 2% BSA in TBST or 5% skim milk in TBST at room temperature for 1 hour. As primary antibodies, rb-GAD65/67 (1:1000), mo-NeuN (1:1000), mo-Vgat (1:700), and mo-actin (1:2000) were used, and the primary antibodies were diluted with 2% BSA in TBST, reacted at 4° C. for 16 hours, and then washed with X TBST. As secondary antibodies, mo-HRP (1:5000) and rb-HRP (1:5000) were used, and the secondary antibodies were diluted in 2% skim milk in TBST or 2% BSA in TBST, reacted for 1 hour, and then developed on films. As control antibodies, mo-tubulin (Millipore, 05-661, 1:2000) and mo-actin (Santa cruz, SC-47778, 1:2000) were used.
As a result, when treated with MANF at 10-50 ng/ml, at 30 ng, the NeuN increased 1.6-fold and the amount of GAD65/67 and vGAT protein increased about 2.5-fold, and the NeuN, GAD65/67 and vGAT protein all increased the most at 30 ng/ml concentrations (
Next, for proliferating neural progenitor cells, Sox2 (mo-Sox2: R&D system, MAB2018, 1:1000), a Type 1 neural progenitor cell marker, and DCX (goat-DCX: Santa cruz, SC-8066, 1:1000)), a migrating neural progenitor cell marker that initiates Type 3 differentiation, were immunoblotted, and as a result, when the MANF was added at 20-500 ng/ml, all showed a similar increasing tendency (
Therefore, in the following Examples, experiments were conducted using a concentration of 30 ng/ml, which is the optimal dose of MANF derived from the above experimental results.
To investigate whether or not MANF promotes proliferation of neural progenitor cells, the primary cultured neural progenitor cells are treated with MANF, and then proliferating cells were fluorescently stained with Ki67 antibody, neural progenitor cells with Nestin antibody, immature nerve cells with TuJ1, and mature neural cells with NeuN antibody.
Specifically, the neural progenitor cells were cultured in the same manner as in Example 1, and after removing all the mediums, they were washed once with PBS. After being fixed for 15 minutes with 4% PFA (paraformaldehyde) in PBS, they were washed twice with PBS again. After washing the cover slip to which the cells were attached with PBST, 0.5% Triton X-100-PBST was added thereto and reacted for 10 minutes. Again, blocking was performed with 2% BSA in PBST or 5% normal serum (Normal donkey serum: Jackson lab, 017-000-121, Normal horse serum: Sigma, H0146); and as primary antibodies, rb-Ki67(Abcam, AB15580, 1:500), mo-NeuN(Millipore, MAB377B, 1:500), mo-Tuj1(Sigma, T8660, 1:3000), mo-Flag(Sigma, F1804, 1:500), and mo-Nestin(Millipore, MAB353, 1:200) were added to 2% BSA in PBS and reacted overnight at 4° C. The next day, they were washed with PBST, and then, as secondary antibodies, mo-Alexa 488(Invitrogen, A21202, 1:700), mo-Cy3(Jackson lab, 715-165-151, 1:500), and rb-Alexa 488(Jackson lab, 711-546-152, 1:700) were added to PBST and reacted at room temperature for 1 hour. Cell nuclei were stained with DAPI (1 µg/mL, Sigma), mounted on slides, scanned with a confocal laser microscope, and photographed. Heo SR et al.(2009) and Han AM t al.(2012) were referred to in the above method.
In the case of cell count confirmation and data analysis, the number of cell nuclei labeled with DAPI and the number of cells stained with each differentiation marker were counted, respectively, and the number of each differentiation marker was expressed as a percentage of the number of cell nuclei. In this case, the number of cells that matched exactly in shape and location and had the shape of a nerve cell was counted. For example, in NeuN cell count measurement, the number of cells with a round shape in a nucleus and overlapping staining with DAPI was counted, and nonspecific signals appearing at the edge of the slide were not included. In data analysis, the control group and the experimental group were compared through one-way analysis of variance (ANOVA). The statistical significance of the data was set as p<0.05.
As a result, Ki67-stained proliferating cells and nestin-stained neural progenitor cells were significantly increased compared to the control group (
To prove the effect of MANF on neural stem cell proliferation, siRNA for MANF receptor mRNA was prepared and injected into primary cultured neural progenitor cells (A) and ratte hippocampus (B), and DCX and Ki67 expressing cells were examined.
Specifically, the neural progenitor cells were cultured in the same manner as in Example 1 and treated with trypsin after 3 days. The cells were collected, treated with siRNA, and then seeded at 8×104 per cover slip. The siRNAs for three types of MANF receptor isoforms were treated with 10 and 30 nM each, a total of 30 and 90 nM. The siRNAs used herein are as follows: Negative control scrambled sequence and MANF receptor 1 antisense sequence: UAGAGUGUACGGUAGACAC(SEQ ID NO: 4)), MANF receptor 2 antisense sequence: AUGGUGUUAGAGUGUAGUC(SEQ ID NO: 5)), MANF receptor 3 antisense sequence: AUCGGAAGAGGUUCAUGAC(SEQ ID NO: 6)). On the 1.5th day after siRNA treatment, fixing and staining were performed.
As a result, the number of proliferating Ki67-stained cells and cells stained with DCX, a differentiating nerve cell marker, was reduced significantly in the case of siRNA treatment compared to the case of treatment with scrambled RNA as a control group (siCON), thereby proving that the MANF promotes the proliferation and differentiation of neural stem cells (
MANF receptor siRNA was injected into the hillus region of the rat hippocampus, and after 1 and 5 days, the rat brain tissue was obtained and stained with Ki67 and DCX antibodies. As a result, the number of cells stained with Ki67 and DCX in the siRNA injection group was reduced by about 50%, respectively, compared to the scrambled RNA injection group (
In order to efficiently investigate the differentiation of the primary neural progenitor cells into GABAergic nerve cells by MANF, a plasmid (GAD-GFP) capable of easily and effectively observing and detecting the differentiation into the GABAergic nerve cells with the naked eye by recombining green fluorescent protein (GFP), a fluorescent protein, into the promoter region of the human GAD gene was used. When the activity of the promoter is increased, the differentiation into GABAergic nerve cells is promoted, and whether or not the activity of the promoter is increased can be monitored by the expression level of a reporter gene operably linked thereto. Accordingly, it can be seen that the differentiation into GABAergic nerve cells is promoted when the expression level of the reporter gene is increased. In addition, it is possible to easily observe the differentiation of GABAergic nerve cells using a transcription factor that binds to the promoter.
Specifically, on day 3 after culturing the primary neural progenitor cells, the cells were separated from the dish with 0.05% trypsin and subcultured, and then all groups were transfected with GAD-GFP DNA. The cells were seeded in a 24-well plate and cultured in N2 medium containing 10 ng/mL bFGF for 24 hours. N2 medium for differentiation without bFGF was treated with MANF at a concentration of 30 ng/ml, and after 3 and 5 days, it was fixed and stained.
As a result, when treated with MANF at a concentration of 30 ng/ml, the number of NeuN-stained cells increased to 10% after 3 days and to 50% after 5 days, but there was no greater increase in the MANF-treated group, and GFP-positive cells increased compared to the Con group, whereby it can be seen that the MANF promotes the differentiation into GABAergic nerve cells in the process of neural cell differentiation (
A MANF gene (SEQ ID NO: 2) was inserted into an adeno-associated virus 2(AAV2) vector to produce a MANF expression vector (MANF-AAV), which was prepared as a recombinant virus and amplified, concentrated to 1012-13 vg/ml. Then, human mesenchymal stem cells (hMSC) were treated at an MOI of 104. As the human mesenchymal stem cells, a bone marrow-derived MSC cell line prepared by Catholic University of Korea was used, which was cultured using 10% FBS medium or MSC GM (Cambrix) medium.
In addition, as a control, recombinant GFP-AAV containing a GFP expression vector (GFP-AAV) in which the GFP gene (SEQ ID NO: 3) was inserted into the AAV2 vector was prepared as a control virus, and concentrated to 1012-13 vg/ml. Then, MSC was treated at an MOI of 104.
The MANF-AAV-hMSC was treated with trypsin before injection into the brain, separated from the culture dish, and then treated with a trypsin inhibitor (300 mg/60 ml N2 media). After accurately counting the number of live cells using trypan blue, it was adjusted to 7.5×104/µl to be suspended in an injection medium (0.7%p/s, 20 mM HEPES (pH7.2), 0.5% glucose in saline), and 2 ul was injected into the brain.
6-week-old male Sprague-Dawley rats (200-250 g) were purchased from the Orient Animal Breeding Center (Charles River Research Institute, Gyeonggi-do, Korea). The rats were randomly housed 2-3 rats per cage to avoid social stress. The breeding condition was a condition in which a certain temperature range (23 ± 2° C.), humidity range (60 ± 10%) and a 12-hour light-dark cycle were maintained and free access to water and feed was provided.
Memory impairment and autism models were prepared by administering IBO to the entorhinal cortex of the rats, wherein the IBO destroys granule cells of the dentate gyrus (DG) and pyramidal cells of the hippocampus, which receive nerve signals input from the entorhinal cortex. Specifically, the rats were anesthetized with equitensin (10% ethanol containing 350 mM pentobarbital sodium, 250 mM chloral hydrate, 85 mM MgSO and 40% propylene glycol). The incisor bar of a stereotaxic device (Stoelting Co., U.S.A.) was placed 3.4 mm below the interaural line, and the injection needle angle was fixed at 10 positions right from the center of the sagittal plane. 1.5 ul of IBO (1 mg/ml) was injected into the entorhinal cortex of the rat using the stereotaxic device. The IBO was injected into three locations of first, AP: -8.4, ML: -4.8, DV: -4.6; Second, AP; -8.4, ML: -4.8, DV: 2.3; Third, AP: -8.8, ML: - 3.65, DV: -3.4 (
After 2-3 IBO injections, each group was randomly classified into an IBO-administrated group (negative control group), and a GFP-AAV-hMSC-administrated group (GFP-AAV) and a MANF-AAV-hMSC-administrated group (PLGF-AAV) as a control group. A rest period of one week was provided. No drug was administered to the Con group (Control, positive control group) consisting of normal rats; saline was administered to the IBO-administrated group; MSC introduced with GFP-AAV by the method of Example 4 was administered to the GFP-AAV-hMSC-administrated group (GFP-AAV); and MSC introduced with MANF-AAV by the method of Example 4 was administered to the MANF-AAV-hMSC-administrated group (MANF-AAV).
The effects of enhancing memory ability and ameliorating anxiety disorders according to administration of MANF was investigated for the IBO-administered memory impairment and autism model prepared as in Example 5.
The Y-shaped maze experiment was performed first among the behavioral experiments (Con group n=8, IBO-administered group n=7, GFP-AAV-administered group n=8, MANF-AAV-administered group n=7). The experimental method was performed according to the information described in Heo H et al. (2009). In the Y-shaped maze where a visual cue was installed at the end of each arm while lights and cams were installed on the ceiling and the surroundings were covered with curtains, it was checked that the rats entered each arm (checked for 8, 10, 12 minutes). The formula for formulating the probability of success was converted into data by dividing the number of times entering each of the three arms by the number of times entering all arms minus 2 and making it a percentage. All results were statistically processed using ANOVA test.
It was performed according to the method described in Heo Het al. (2009) for the same number of rats as in each group of Example 6-1. This experiment is composed of a semi-automatic system with a shuttle room. These rats were trained to escape the light by entering a dark room through an acrylic door when the light was turned on. This training was repeated 3 times a day for 3-4 days until the rat entered the dark room within 20 seconds (adaptation). All rats were successfully trained to enter the dark room within 20 seconds on the last training day. After performing the adaptation training on the last day of training, the rats were placed in a bright room, and when they entered the dark room, the door was closed by hand, and an electric shock (1 mA, based on 300 g) was applied to the paws through a grill for 3 seconds. Exactly 24 hours after the adaptation training, the rats were placed in the bright room again, and the latency time to enter the dark room was measured for 720 seconds (confinement experiment).
The same number of rats as in each group of Example 6-1 was subjected to the Morris water maze experiment in a round, rust-free and inner surface-white swimming pool (diameter 160 cm; height 60 cm). The pool was filled with water (maintained at 23.0 ± 1.0° C.) to a depth of 50 cm, and an invisible platform (15 cm, round and white) was hidden 1.0 cm below the water surface and placed in the center of the northeast quadrant. Each rat was trained once a day for 4 days to find the hidden platform. Training was started by randomly placing the rats in the water so as to the pool wall in one of the four quadrants. During each training, the rats were allowed to find the platform for up to 60 seconds and to rest for 1 minute after finding the platform. The average time of the four quadrant tests was defined as the waiting time for escape per group on the training day. The final experiment measured the time the rat stayed where the platform was for 60 seconds after removing the platform (probe trial). Swimming time and training length were tracked and recorded using a video camera. The tracking was performed along the trajectory of the rat indicated by black dots on a white background. The captured video pictures were analyzed with a video tracking system (Ethovision water maze program, Noldus Information Technology, Wogeningen, The Netherlands). The analyzed information included the time of swimming in the target quadrant, and the number of crossings the imaginary platform to find the removed platform.
As a result of the experiment of Examples 6-1 to 6-3, as shown in
In order to measure the anxiety behavior of the same number of rats as in each group of Example 6-1, a behavior experiment apparatus composed of two closed arms and two open arms of a cross maze and floating high in the air was used. The rat, placed in the middle of the cross-shaped maze to face the open arm, freely explored the maze for 10 minutes. The anxiety disorder of the rats was tested as a tendency to avoid the exposed open arm and stay in the closed arm. It was analyzed with a video tracking system (Ethovision EPM program, Noldus Information Technology, Wogeningen, The Netherlands).
As a result, the time spent in the open arm increased in the MANF-AAV-administrated group compared to the IBO-administrated group, indicating that the anxiety disorders were ameliorated (
In order to measure the anxiety behavior of the same number of rats as in each group of Example 6-1, a 100 cm*100 cm space composed of black acrylic was divided into squares of 20 cm*20 cm on the floor to divide the space, wherein the central nine compartments were set as the center zone, and the other areas were set as the border zone. The central 9 compartments were illuminated with a slightly brighter light to measure the time in the relatively bright center zone and the dark border zone.
As a result, the time in the center decreased in the IBO group, but the time in the center significantly increased in the MANF group compared to the IBO group, and also increased compared to the MSC group, so the anxiety disorder was resolved at a level similar to that of the control group (Con) (
The defects in sociability of the IBO-administered memory impairment and autism model prepared as in Example 5, and whether these defects could be recovered when MANF-AAV-hMSC was administered were measured through behavioral experiments.
Specifically, the sociability was tested in the social open field. Rats were adapted to the recording environment for 30 min, and then adapted to a social open field space composed of black acrylic for 10 min. Strange rats were placed in a cylindrical cage allowing for olfaction and minimal contact, and placed in the center of the edge of the arena. The movements of the test rats were recorded for 10 minutes and analyzed by the ethovision 3.1 program. In addition, the range of sociability was analyzed by setting 10 cm around the cylinder in which the strange rats were placed.
As a result, the time spent in the destination area and the time showing interest in the target individual (sniffling) were similarly shorter than those of normal rats in the IBO-administered group and the GFP-AAV-hMSC-administered group, and significantly longer in the MANF-AAV-hMSC-administered group (
A three-room experiment was conducted to see if social cognition, sociability and social sexual preference were restored when MANF-AAV-hMSC was administered to the IBO-administered memory impairment and autism model prepared as in Example 5.
Specifically, an experimental site is composed of three rooms having a transparent acrylic wall and a small door, wherein each room was 50 cm long × 100 cm wide × 50 cm high. The olfaction and minimal contact of the test rats to the strange rats was allowed through the cylindrical cage. Prior to the test, the test rats were placed in the middle room, and allowed to adapt for 5 minutes after both doors were closed. The test was divided into the following sessions I, II and III and performed.
To measure sociability, two cylindrical cages were placed in each edge room, one containing a strange rat and the other empty. The test rats were placed in the middle room, moved freely in the three rooms, and had access to two cages for 10 minutes. The movement of the rat was recorded and analyzed as the areas of none and strange rat 1 through ethovision 3.1 program.
In order to build a new sociality for a new object and analyze the social cognition of the object that has already formed sociality, a new rat (strange rat) was added to the cage that was new in session I. After opening both doors so that the test rat can access all three chambers, the test rat was placed in the middle chamber and allowed to move freely for 10 minutes. The movement of the rat was recorded and analyzed as the areas of a familiar rat and a strange rat through ethovision 3.1 program.
To measure sexual preference and social cognition by analyzing contact with female rats, female and male rats were placed in cylindrical cages in each room, and the cages in which the test rats were in contact more frequently, and the contact times were measured. The movement of the rat was recorded and analyzed as access time and frequency for each cage per session through ethovision 3.1 program.
As shown in
As shown in
In addition, as shown in
From this, it can be seen that the administration of MANF restores social cognition, sociability and social sexual preference.
For immunohistochemical analysis after the behavioral experiment of Example 8, brain tissues of 4 or more rats from each group were obtained and brain sections were immunostained.
As an experimental method, the one described in Heo et al. (2009) was modified and used. Rats were transcardially perfused with 4% PFA in PBS, and immersed and fixed in 4% PFA in PBS for 4 hours. Thereafter, the brain tissue was non-frozen in 30% sucrose in PBS, then frozen to optimal cutting temperature (OCT) mixture and stored at -80° C. Brain tissue sections were cut in a cold place through a 35 µm-thick coronal plane. The brain tissue sections were immersed in a stock solution (30% glycerol, 30% ethylene glycol in PBS) and stored at 4° C.
Thereafter, a TUNEL assay was performed to analyze the death degree of brain neural cells. The stored brain slices were fixed at room temperature for 10 minutes using 4% paraformaldehyde, washed twice with PBS, and were enzymatically reacted for 1 hour in a 37° C. thermostat in which humidity was maintained according to the protocol of the TUNEL assay kit (Roche, 11684795910). Thereafter, they were washed three times with PBS, and the cell nuclei were labeled with 1 ug/ml propidium iodide (Sigma, P4864, 1:3000) to analyze cell death.
As a result, as shown in
The brain tissue stored in the same method as the immunostaining of Example 9-1 was washed twice with PBS, permeated in 0.5% Triton X-100 for 20 minutes, and cultured in 2N HCl at 37° C. for 30 minutes. Thereafter, blocking was performed in 15% standard serum, 3% bovine serum albumin (bio-WORLD, Dublin, OH, USA) and 0.1% Triton X-100 in a free-floating state for 2 hours. The tissue was doubly stained at 4° C. for 16 hours using BrdU (abcam, 1:700) antibody, SOX2 (R&D system, MAB2018, 1:2000), DCX (Santacruz, sc8066, 1:1000), NeuN (Millipore, MAB377B, 1:700), CNPase (Abcam, ab6319, 1:700), vGluT1 (Millipore, MAB5502, 1:700), GAD67 (Millipore, MAB5406, 1:2000) as primary antibodies. As secondary antibodies, mo-Alexa 488 (Invitrogen, A21202, 1:700), mo-Cy3 (Jackson lab, 715-165-151, 1:500), rb-Alexa 488 (Jackson lab, 711-546-152, 1:700), rat-Alexa 488 (Abcam, ab6326, 1:700), etc. were used. Immunostained tissues were scanned with a confocal microscope (LSM510, LSM800 Carl Zeiss, Oberkochen, Germany).
The number of differentiation markers in the hippocampus of each experimental animal was shown by counting the number of DAPI-labeled cells in the double and triple photographed slides and counting the number of each cells labeled by fluorescently labeling each differentiation marker, NeuN, CNPase, GAD and vGluT1. Here was counted the number of cells labeled with the secondary antibody that is precisely matched in shape and location and has the shape of a cell.
As a result, as shown in
As shown in
Changes in cholinergic neurons were investigated when MANF-AAV-hMSC was administered using immunostaining for the IBO-administered memory impairment and autism model prepared as in Example 5.
Specifically, rats were perfused with 4% PFA in PBS, and brains were removed. The brain was fixed at 4° C. for 4 hours, and then dehydrated using PBS containing 30% sucrose at 4° C. for 48 hours. The brains were then frozen in block form and stored at -80° C. using an optimal temperature compound. The tissues were prepared into 30 µm-thick coronal sections and stored at 4° C. in a stock solution (PBS containing 30% glycerol and 30% ethylene glycol). Thereafter, they were permeated in 0.5% Triton X-100-PBS for 20 minutes, blocked in 10% normal serum, 3% BSA, and 0.1% Triton X-100-PBS at room temperature for 1 hour, and then immunostained using the primary antibody of ChAT (Millipore, AB 144p, 1:200), and counted. The immunostaining was performed every 0.3 mm in each brain slice AP -4.0 to -5.2 mm in the ventral hippocampus (ventral hippocampal regions, vHP).
As a result, as shown in
According to the results of the above examples, the administration of MANF promotes the differentiation of cholinergic and/or GABAergic nerve cells in memory impairment and autism models to induce nerve regeneration, exhibits effects of enhancing memory and ameliorating anxiety disorders, and ameliorates social cognition, sociability and decline in social sexual preference, whereby a composition for preventing or treating neuropsychologic diseases such as autism, ADHD, mental retardation disorder, and developmental disorder can be provided.
From the above description, those skilled in the art to which the present invention pertains will understand that the present invention may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be construed as including the meaning and scope of the claims to be described later rather than the detailed description above, and all changed or modified forms derived from the equivalent concepts thereof.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2020-0127087 | Sep 2020 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2021/013342 | 9/29/2021 | WO |
